Brazil's Anvisa Approves New Drug for Fabry Disease Treatment

Brazil's health regulator Anvisa approved a new drug for Fabry disease, a rare lysosomal storage disorder causing fat accumulation in cells and damaging kidneys, heart, and nervous system. The approval expands treatment options in Brazil, though the specific drug and its efficacy details remain unspecified. This is a regulatory milestone for rare-disease patients in the country.